Liraglutide Calculator
Liraglutide (also known as Victoza) reconstitution and dosage reference — calculate vial concentration, BAC water volume, and exact syringe units below.
Also known as: Victoza, Saxenda
At the reference preset of a 18mg Liraglutide vial reconstituted with 3 mL of bacteriostatic water, a 0.6mg dose measures 10 units on a U-100 insulin syringe.
Liraglutide is a once-daily GLP-1 receptor agonist marketed as Victoza (type 2 diabetes) and Saxenda (chronic weight management).
- Concentration
- 6 mg/mL
- Draw volume
- 0.1 mL
- Units (U-100)
- 10
- Doses per vial
- ≈ 30
- Reference preset
- 18mg · 3mL · 0.6mg
Reference values from the default preset — adjust the calculator below for your vial.
What is Liraglutide?
Liraglutide is a once-daily GLP-1 receptor agonist marketed as Victoza (type 2 diabetes) and Saxenda (chronic weight management). Unlike semaglutide and tirzepatide, liraglutide is dosed daily rather than weekly. The Saxenda titration starts at 0.6 mg/day and steps up weekly to a 3.0 mg maintenance dose. It is most commonly supplied as a pre-filled multi-dose pen, though compounded vials are available.
| 18 mg | lyophilized powder |
| 0.6 mg | ≈ 10 U-100 units (at 18mg / 3mL) |
| 1.2 mg | ≈ 20 U-100 units (at 18mg / 3mL) |
| 1.8 mg | ≈ 30 U-100 units (at 18mg / 3mL) |
| 2.4 mg | ≈ 40 U-100 units (at 18mg / 3mL) |
| 3 mg | ≈ 50 U-100 units (at 18mg / 3mL) |
How it's typically prepared
Most pre-filled liraglutide pens arrive ready to use and are not reconstituted manually. For compounded vials supplied as a solution or powder, reconstitute with bacteriostatic water, swirl gently rather than shaking, and store refrigerated at 2–8 °C. An 18 mg vial reconstituted in 3 mL gives a 6 mg/mL concentration, so a 0.6 mg starting reference amount corresponds to 0.1 mL — 10 units on a U-100 insulin syringe.
Why liraglutide is dosed daily
Liraglutide is a GLP-1 receptor agonist with a half-life of roughly 13 hours, which is why its labelled schedules are once-daily rather than the once-weekly cadence used by semaglutide and tirzepatide. The FDA labels titrate the dose upward in weekly steps to let gastrointestinal tolerability develop before reaching the maintenance amount — 3.0 mg/day for Saxenda in chronic weight management and up to 1.8 mg/day for Victoza in type 2 diabetes. The titration ladder below is reproduced from the Saxenda prescribing information as an educational reference.
On a U-100 insulin syringe, the draw volume depends entirely on the concentration of the vial or pen. A compounded 18 mg vial reconstituted in 3 mL sits at 6 mg/mL, so each 0.6 mg titration step is 0.1 mL — 10 units — and the 3.0 mg maintenance amount is 0.5 mL, or 50 units. The calculator above recomputes these figures for any vial size and diluent volume entered; the numbers are reference math, not a personalised dose.
Liraglutide Titration Schedule (Saxenda label)
Reference titration ladder from the Saxenda (liraglutide) FDA prescribing label for chronic weight management. Liraglutide is dosed once daily; each step is held for one week. This schedule is informational, not personalised advice.
| Starting week | Dose | Notes |
|---|---|---|
| Week 1 | 0.6 mg/ day | — |
| Week 2 | 1.2 mg/ day | — |
| Week 3 | 1.8 mg/ day | — |
| Week 4 | 2.4 mg/ day | — |
| Week 5 | 3 mg/ day | Maintenance |
Liraglutide Side Effects
Adverse events summarised on the Saxenda (weight management) and Victoza (type 2 diabetes) FDA prescribing labels are predominantly gastrointestinal and most common during weekly dose escalation. The list below is an educational summary of those labels, not a complete safety profile. Both labels carry a boxed warning for thyroid C-cell tumours based on rodent studies.
- Nausea
- Diarrhea
- Constipation
- Vomiting
- Decreased appetite
- Dyspepsia (indigestion)
- Headache
- Fatigue
- Dizziness
- Injection-site reactions
- Pancreatitis
- Gallbladder disease (cholelithiasis, cholecystitis)
- Acute kidney injury (usually from dehydration via GI fluid loss)
- Hypoglycemia (mainly when combined with insulin or a sulfonylurea)
- Increased resting heart rate
- Suicidal ideation (labelled monitoring caution for weight-management use)
- Thyroid C-cell tumours (boxed warning; based on rodent data)
Frequently asked questions
- Is liraglutide dosed daily or weekly?
- Liraglutide is dosed once daily. This is its main practical difference from weekly semaglutide and tirzepatide, and follows from its roughly 13-hour half-life.
- What is the maintenance dose on the Saxenda label?
- The Saxenda (liraglutide) label for chronic weight management titrates to a 3.0 mg/day maintenance amount. Victoza for type 2 diabetes typically tops out at 1.8 mg/day.
- What is the difference between Victoza and Saxenda?
- Both are liraglutide. Victoza is the brand approved for type 2 diabetes (up to 1.8 mg/day); Saxenda is the brand approved for chronic weight management (up to 3.0 mg/day). The molecule is identical — the brands differ in indication and maximum labelled dose.
- How many insulin-syringe units is a liraglutide dose?
- It depends on the concentration. For an 18 mg vial reconstituted in 3 mL (6 mg/mL), a 0.6 mg amount is 10 units and a 3.0 mg amount is 50 units on a U-100 syringe. Enter your vial size and diluent volume in the calculator to convert any target amount.
- Why does the dose start so low and step up weekly?
- The weekly titration on the FDA labels is intended to let gastrointestinal tolerability develop gradually before the maintenance amount is reached. Each step is held for about a week before increasing.
Related references
- Semaglutide — dosage calculator, reconstitution chart, and sources.
- Tirzepatide — dosage calculator, reconstitution chart, and sources.
- Orforglipron — dosage calculator, reconstitution chart, and sources.
PeptideDose is an educational reference. It is not medical advice and does not replace consultation with a licensed healthcare provider. Doses shown in presets are derived from published protocols and product labels — they are not personal recommendations.
